
The drug’s approval permits its use in patients aged two years and older with Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.
from World News Headlines, Latest International News, World Breaking News - Times of India https://ift.tt/2KqBt6I
via
IFTTT
0 comments:
Post a Comment